Federal Bill Spotlights Novel Therapies for Veteran Mental Health Crisis

WASHINGTON, D.C. – February 03, 2026 – A new bipartisan bill introduced in the U.S. Congress could fundamentally reshape mental healthcare for the nation’s veterans, offering a pathway to innovative treatments that lie beyond the scope of conventional medicine. The legislation, named the 'Expanding Veterans’ Access to Emerging Treatments Act of 2026' (H.R. 7091), specifically includes a novel, non-hallucinogenic compound known as MEAI, marking a significant moment for both veteran advocacy and the burgeoning field of neuro-therapeutic medicine.

Introduced by Representatives Jack Bergman (R-MI) and J. Luis Correa (D-CA), co-chairs of the Congressional Psychedelics Advancing Therapies (PATH) Caucus, the bill directs the Department of Veterans Affairs (VA) to establish a comprehensive research and treatment program for a range of emerging therapies. This move signals a growing recognition in Washington that new solutions are desperately needed to address the persistent challenges of post-traumatic stress disorder (PTSD), alcohol use disorder (AUD), depression, and other conditions plaguing the veteran community.

If passed, H.R. 7091 would authorize the VA to conduct clinical trials and create extended access protocols—often called 'compassionate use' programs—for substances that have shown therapeutic promise. The bill explicitly lists psilocybin, MDMA, ibogaine, and ketamine, alongside MEAI, representing a landmark legislative acknowledgment of their potential.

A First for MEAI, A New Hope for Treatment

The inclusion of MEAI (5-methoxy-2-aminoindane) is particularly noteworthy. It is the first time the compound, a proprietary asset of clinical-stage biotech company Clearmind Medicine Inc., has been named in U.S. federal legislation. Unlike psilocybin or MDMA, MEAI is classified as a non-hallucinogenic neuroplastogen. This new class of drugs is designed to promote neuroplasticity—the brain’s ability to form new neural connections and rewire itself—without inducing the profound perceptual changes associated with classic psychedelics.

This distinction could be critical for its path to mainstream acceptance. A non-hallucinogenic option may lower barriers to treatment, reducing the need for intensive, hours-long clinical monitoring sessions and potentially making the therapy more accessible and less intimidating for a broader patient population. Clearmind is currently evaluating MEAI in an FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder, with research sites at prestigious institutions including Johns Hopkins University and the Tel Aviv Sourasky Medical Center. Early data from the first patient cohort has shown a favorable safety profile and promising signals of efficacy, including reduced alcohol cravings.

“We so greatly appreciate Congress introducing H.R. 7091, which offers a transformational opportunity for veterans suffering from alcoholism, post-traumatic stress disorder and other conditions to access emerging, promising therapies,” said Clearmind Medicine CEO Dr. Adi Zuloff-Shani in a recent statement. “We also appreciate the recognition of MEAI, a non-hallucinogenic neuroplastogen with the transformative potential to improve the health of veterans.”

A Shifting Paradigm in Policy and Medicine

The introduction of H.R. 7091 reflects a significant paradigm shift, moving the conversation around these substances from the fringes of medical science toward the center of federal policy discussions. The bill is not just about one compound but about creating a formal, government-supported framework for exploring solutions to what many consider an urgent public health crisis.

Advocates have hailed the bill as a crucial step forward. Melissa Lavasani, Founder and CEO of the Washington, D.C.-based Psychedelic Medicine Coalition, praised the legislation's potential. "This bill, with the inclusion of MEAI and other innovative therapies, forges a new vocabulary for evidence-based psychedelic healing,” she commented, framing it as a legitimate federal pathway for veterans who have exhausted other treatment options.

The VA itself has shown an increasing willingness to investigate novel treatments, and this bill would provide the explicit authority and mandate to accelerate that work. It requires the Secretary of Veterans Affairs to appoint a lead administrator for the program within 60 days of enactment and to report on its findings to Congress within a year, ensuring accountability and progress.

Market Validation and the Road Ahead

The legislative validation has not gone unnoticed by the biotech industry and investors. Following the announcement, shares of Clearmind Medicine (Nasdaq: CMND) experienced a notable surge, reflecting investor optimism about MEAI’s future. For a clinical-stage company with a market capitalization of around $3.35 million, such legislative recognition provides a powerful form of validation that can attract further investment and partnerships, de-risking the long and expensive process of drug development.

While H.R. 7091 represents a significant step, its journey through the legislative process is just beginning. The bill has been referred to the House Committee on Veterans' Affairs, where it will be debated, potentially amended, and voted on before it can advance further. The path to becoming law is long and uncertain.

However, the bipartisan sponsorship of the bill and the growing chorus of support from veteran groups, scientists, and advocacy organizations suggest a powerful momentum. The introduction of the Expanding Veterans’ Access to Emerging Treatments Act of 2026 has already succeeded in elevating the conversation, pushing innovative science into the halls of power and offering a tangible symbol of hope for veterans and their families across the country.